Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PsychoGenics Inc.
Deal Watch: Aging-Focused Calico Taps Start-Up Terray For Discovery
Terray/Calico tie-up will focus on small molecule discovery for diseases of aging, including cancer. Lilly, AstraZeneca sign discovery pacts with Nimbus and Illumina, respectively.
Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Sunovion’s TAAR1 Agonist Brings Something New To CNS Arena
Sunovion’s new schizophrenia candidate is generating investor attention given its first-in-class mode of action. Newly published clinical results appear to bear out its promise in a sector where there’s been limited innovation.
Dainippon Lays Out R&D Table Ahead Of Latuda Challenges
Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.
- Contract Research, Toxicology Testing-CRO
Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.